Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Sebesta

Urology El Paso, TX Medical Doctor

NPI 1447218409 CMS profile 156345

2000 Trans Mountain Rd, El Paso, TX 79911

Open in the dashboard

General payments

$6,636

56 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Sebesta of El Paso, TX is reported in the CMS Open Payments database as having received $6,636 across 56 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,012 14
2024 General $1,429 9
2021 General $563 11
2020 General $156 3
2019 General $2,475 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Sebesta
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Michael Sebesta were reported at $2,012. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Michael Sebesta Urology median Middle half National median
2019 $2,475 $480 $147–$1,201 $163
2020 $156 $246 $87–$645 $114
2021 $563 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $1,429 $563 $170–$1,464 $164
2025 $2,012 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Agiliti Surgical, Inc. $1,670 11 payments
  2. PROCEPT BioRobotics Corporation $1,509 8 payments
  3. NeoTract Inc. $1,333 8 payments
  4. Boston Scientific Corporation $1,163 14 payments
  5. Coloplast Corp $355 8 payments
  6. Teleflex LLC $307 4 payments
  7. Zimmer Biomet Holdings, Inc. $220 2 payments
  8. DePuy Synthes Sales Inc. $78 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,101 12 payments
  2. Food and Beverage $2,535 44 payments
Products named General payments · program years 2019–2025
  1. Sonablate HIFU $1,670 11 payments
  2. AQUABEAM ROBOTIC SYSTEM $1,509 8 payments
  3. UROLIFT $1,333 8 payments
  4. General BPH $460 3 payments
  5. GREENLIGHT $393 2 payments
  6. UroLift System $307 4 payments
  7. Juggerknotless Soft Anchor $220 2 payments
  8. TITAN $178 4 payments
  9. LITHOVUE $156 3 payments
  10. Koelis Trinity MRI/US Fusion $131 1 payment
  11. Other $487 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,018

Median for Urology: 1,053

Drug cost

$69,791

Median for Urology: $101,464

Branded share of claims

19.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 53 $57,485
Tamsulosin Hcl Generic 363 $4,513
Finasteride Generic 217 $3,069
Solifenacin Succinate Generic 43 $1,686
Alfuzosin Hcl Er Alfuzosin Hcl Brand 23 $641
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 84 $458
Betamethasone Valerate Generic 18 $425
Ibuprofen Generic 40 $337
Ciprofloxacin Hcl Generic 29 $310
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 18 $275

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$47,264

Medicare's payments for the services billed

Medicare patients

151

Average age 75

Services billed

814

33 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Arthritis 42%
Chronic kidney disease 34%
Ischemic heart disease 30%
Atrial fibrillation 21%
COPD 21%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record